These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12377565)

  • 21. Structural proteomics in drug discovery.
    Tari LW; Rosenberg M; Schryvers AB
    Expert Rev Proteomics; 2005 Aug; 2(4):511-9. PubMed ID: 16097885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era.
    Dougherty TJ; Miller PF
    IDrugs; 2006 Jun; 9(6):420-2. PubMed ID: 16752312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent developments in structural proteomics for protein structure determination.
    Liu HL; Hsu JP
    Proteomics; 2005 May; 5(8):2056-68. PubMed ID: 15846841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NMR in structural genomics to increase structural coverage of the protein universe: Delivered by Prof. Kurt Wüthrich on 7 July 2013 at the 38th FEBS Congress in St. Petersburg, Russia.
    Serrano P; Dutta SK; Proudfoot A; Mohanty B; Susac L; Martin B; Geralt M; Jaroszewski L; Godzik A; Elsliger M; Wilson IA; Wüthrich K
    FEBS J; 2016 Nov; 283(21):3870-3881. PubMed ID: 27154589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of structural genomics: the first quindecennial.
    Grabowski M; Niedzialkowska E; Zimmerman MD; Minor W
    J Struct Funct Genomics; 2016 Mar; 17(1):1-16. PubMed ID: 26935210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New routes for drug discovery.
    Jain KK
    Drug Discov Today; 2002 Sep; 7(17):900-2. PubMed ID: 12546932
    [No Abstract]   [Full Text] [Related]  

  • 27. Genomics and proteomics tools for compound mode-of-action studies in drug discovery.
    Kley N; Ivanov I; Meier-Ewert S
    Pharmacogenomics; 2004 Jun; 5(4):395-404. PubMed ID: 15165175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural proteomics by NMR spectroscopy.
    Shin J; Lee W; Lee W
    Expert Rev Proteomics; 2008 Aug; 5(4):589-601. PubMed ID: 18761469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
    Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
    Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based approaches to antibiotic drug discovery.
    Nicola G; Abagyan R
    Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.2. PubMed ID: 19235149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
    Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
    Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yeast genomics and proteomics in drug discovery and target validation.
    Parsons AB; Geyer R; Hughes TR; Boone C
    Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput protein crystallography and drug discovery.
    Tickle I; Sharff A; Vinkovic M; Yon J; Jhoti H
    Chem Soc Rev; 2004 Oct; 33(8):558-65. PubMed ID: 15480479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methods for the successful crystallization of membrane proteins.
    Moraes I; Archer M
    Methods Mol Biol; 2015; 1261():211-30. PubMed ID: 25502202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics.
    Rachakonda S; Cartee L
    Curr Med Chem; 2004 Mar; 11(6):775-93. PubMed ID: 15032731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of putative non-host essential genes and novel drug targets against Acinetobacter baumannii by in silico comparative genome analysis.
    Uddin R; Masood F; Azam SS; Wadood A
    Microb Pathog; 2019 Mar; 128():28-35. PubMed ID: 30550846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets.
    Bodovitz S; Joos T
    Trends Biotechnol; 2004 Jan; 22(1):4-7. PubMed ID: 14690616
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel genetic techniques and approaches in the microbial genomics era: identification and/or validation of targets for the discovery of new antibacterial agents.
    Pucci MJ
    Drugs R D; 2007; 8(4):201-12. PubMed ID: 17596107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional genomics to new drug targets.
    Kramer R; Cohen D
    Nat Rev Drug Discov; 2004 Nov; 3(11):965-72. PubMed ID: 15520818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postgenomic strategies in antibacterial drug discovery.
    Brötz-Oesterhelt H; Sass P
    Future Microbiol; 2010 Oct; 5(10):1553-79. PubMed ID: 21073314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.